Study validating first prognostic test for IBD begins in US

A new clinical study validating the first prognostic test for inflammatory bowel disease (IBD) has started in the US.

The study is being jointly funded by the Crohn’s & Colitis Foundation and PredictImmune, a UK developer of prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases.

The PRECIOUS study is a multi-centre, observational study of patients with active Crohn’s disease or ulcerative colitis, who are not receiving systemic steroids, immunomodulators or biologics.

It will recruit up to 200 patients from about 15 centres across the US. The patients recruited by New York University/Bellevue are the first to join the study, which will continue to recruit. Patients’ progress will be tracked up for up to 12 months following initial blood sample collection.

Study patients will be classified at diagnosis into high-risk and low-risk cohorts using PredictImmune’s PredictSURE IBD biomarker.

PredictSURE IBD stratifies patients based on their risk of subsequently experiencing a severe disease course, which is characterised by the requirement for multiple escalations in treatment due to frequently relapsing or chronically active disease.

The study will provide important data towards validation of PredictSURE IBD in a diverse US patient population.

PredictSURE IBD is based on 10 years of extensive research into gene expression profiling of CD8+ T cells by researchers at Professor Ken Smith’s laboratory at the University of Cambridge, UK.

The start of the study follows the recent announcement that PredictImmune has entered into an exclusive commercial partnership with KSL Biomedical (KSL), to promote and provide PredictSURE IBD, throughout North America.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

AbCellera raises $105m to advance antibody drug discovery platform

AbCellera has closed a $105 million Series B financing to further advance its antibody drug discovery platform. The financing was led by OrbiMed and current...

Novavax expands large-scale manufacturing capacity

Novavax, a late-stage biotech developing next-gen vaccines for serious infectious diseases, has expanded its large-scale manufacturing capacity with the $167 million acquisition of Praha...

Gilead & Arcus partner to develop next-gen cancer immunotherapies

Gilead Sciences and Arcus Biosciences, an oncology-focused biopharma working to create best-in-class cancer therapeutics, have entered into a ten-year partnership to co-develop and co-commercialise...

Atomwise announces partnerships to tackle COVID-19

Atomwise, a San Fran company using AI for small molecule drug discovery, has announced it has fifteen research collaborations underway with leading global universities...

GSK secures additional biopharma capacity via Samsung Biologics partnership

GlaxoSmithKline (GSK) has secured additional manufacturing capacity for its biopharmaceutical portfolio by partnering with South Korea’s Samsung Biologics. As per the agreement, Samsung Biologics will...

Related news

Chimeron Bio & NCBID to develop COVID-19 vaccine

RNA therapeutics company, Chimeron Bio, and George Mason University’s National Center for Biodefense and Infectious Diseases (NCBID), will together develop a COVID-19 vaccine. The vaccine...

AbCellera raises $105m to advance antibody drug discovery platform

AbCellera has closed a $105 million Series B financing to further advance its antibody drug discovery platform. The financing was led by OrbiMed and current...

Novavax expands large-scale manufacturing capacity

Novavax, a late-stage biotech developing next-gen vaccines for serious infectious diseases, has expanded its large-scale manufacturing capacity with the $167 million acquisition of Praha...

Gilead & Arcus partner to develop next-gen cancer immunotherapies

Gilead Sciences and Arcus Biosciences, an oncology-focused biopharma working to create best-in-class cancer therapeutics, have entered into a ten-year partnership to co-develop and co-commercialise...